Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma

被引：4
作者：
Yang L. [1 ,2 ]
Bai Y. [1 ]
Han X. [1 ,2 ]
Shi Y. [3 ,4 ]
Liu H. [1 ]
机构：
[1] Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Beijing National Laboratory for Molecular Sciences, Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering, Peking University, Beijing
[2] Department of Pharmacy, Shanxi Medical University, Taiyuan
[3] Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
[4] Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing
来源：
Journal of Analysis and Testing | 2017年 / 1卷 / 3期
基金：
中国国家自然科学基金;
关键词：
Biomarker; Hepatocellular carcinoma; Lipidomics; NP/RP 2D LC-QToF/MS;
D O I：
10.1007/s41664-017-0028-2
中图分类号：
学科分类号：
摘要：
Hepatocellular carcinoma (HCC) accounts for the major primary liver cancer, and its morbidity and mortality rates are very high. Identification of novel biomarkers for the early diagnosis and treatment of this disease is of crucial importance. In this study, a continuous-flow normal-phase/reversed-phase two-dimensional liquid chromatography—quadrupole time-of-flight mass spectrometry (NP/RP 2D LC-QToF/MS) method was used to detect lipid species in human plasma from HCC patients and healthy controls. As a result, the two groups were clearly separated by principal component analysis. Besides, 23 lipid species with corrected p value <0.05 and fold change >1.5 were proposed as potential lipid biomarkers for HCC. Among them, 9 lipid species, including galactosylceramide (36:5), free fatty acid (20:4), phosphatidylethanolamine (40:6), phosphatidylethanolamine (38:6), diacylglycerol (40:5), diacylglycerol (44:2), lactosylceramide (40:3), phosphatidylcholine (40:6), and free fatty acid (22:5), exhibited excellent ability to distinguish HCC patients from healthy controls with the area under the receiver-operating characteristic curve >0.900, showing promising clinical value. Taken together, these results indicate the great potential of NP/RP 2D LC-QToF/MS method in disease diagnosis, which might be helpful in clinical practice. © 2017, The Nonferrous Metals Society of China and Springer Nature Singapore Pte Ltd.
引用
收藏
页码：223 / 232
页数：9
相关论文
共 41 条
[1]  
Forner A., Llovet J.M., Bruix J., Hepatocellular carcinoma, Lancet, 379, 9822, pp. 1245-1255, (2012)
[2]  
El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R., Diagnosis and treatment of hepatocellular carcinoma, Gastroenterology, 134, 6, pp. 1752-1763, (2008)
[3]  
Lok A.S., Sterling R.K., Everhart J.E., Wright E.C., Hoefs J.C., Di Bisceglie A.M., Et al., Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma, Gastroenterology, 138, 2, pp. 493-502, (2010)
[4]  
Chen L., Ho D.W.Y., Lee N.P.Y., Sun S., Lam B., Wong K.-F., Et al., Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker, Ann Surg Oncol, 17, 9, pp. 2518-2525, (2010)
[5]  
Colli A., Fraquelli M., Casazza G., Massironi S., Colucci A., Conte D., Et al., Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review, Am J Gastroenterol, 101, 3, pp. 513-523, (2006)
[6]  
Kassahun W.T., Fangmann J., Harms J., Hauss J., Bartels M., Liver resection and transplantation in the management of hepatocellular carcinoma: a review, Exp Clin Transplant, 4, 2, pp. 549-558, (2006)
[7]  
Spener F., Lagarde M., Geloen A., Record M., What is lipidomics?, Eur J Lipid Sci Technol, 105, 9, pp. 481-482, (2003)
[8]  
Yang L., Li M., Shan Y., Shen S., Bai Y., Liu H., Recent advances in lipidomics for disease research, J Sep Sci, 39, 1, pp. 38-50, (2016)
[9]  
Jiang J., Nilsson-Ehle P., Xu N., Influence of liver cancer on lipid and lipoprotein metabolism, Lipids Health Dis., 5, (2006)
[10]  
Motta M., Giugno I., Ruello P., Pistone G., Di Fazio I., Malaguarnera M., Lipoprotein (a) behaviour in patients with hepatocellular carcinoma, Minerva Med, 92, 5, pp. 301-305, (2001)
12345